16.10.2023 13:00:06 - dpa-AFX: GNW-Adhoc: Tilray Medical Supports New Clinical Trial to Study Medical Cannabis in Glioblastoma Cancer Treatment
CANTANHEDE, Portugal, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Tilray Medical, a
division of Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX:
TLRY) and a global leader in medical cannabis, empowering the therapeutic
alliance between patients and healthcare practitioners to make informed
individualized health decisions, transforming healthcare, today announced their
contribution to an independent clinical trial to research the efficacy of
medical cannabis as a treatment for glioblastoma, a severe form of brain cancer.
The clinical trial will be conducted in Spain, recruiting 30 patients from eight
specialized neuro-oncology medical sites, in partnership with renowned
scientists from the Spanish Research Group of Neuro-Oncology (GEINO) and the
Complutense University of Madrid, with Tilray Medical
(https://www.tilray.com/tilray-medical) providing the pharmaceutical-grade
medical cannabis for the trial (THC/CBD 1:1) for administration to patients. The
trial is funded by the Medical Cannabis Bike Tour (https://www.medicalcannabis-
biketour.com/the-cause/) Foundation charity and is scheduled to commence at
University Hospital 12 de Octubre, on September 5, 2023.
Denise Faltischek, Tilray's Chief Strategy Officer and Head of International
Business, stated, "This groundbreaking trial is more than an opportunity for
Tilray to engage in medical research; it's a beacon of hope for patients
suffering from Glioblastoma. Our role in this initiative exemplifies our
commitment to medical research, leading us one step closer to unlocking the full
therapeutic potential of medical cannabis."
Led by esteemed coordinating investigator Dr. Juan Manuel Sepúlveda Sánchez from
GEINO (https://geino.es/), the clinical trial is a Phase I, open-label,
multicenter, intrapatient dose-escalation to evaluate the safety and profile of
Tilray Medical's T10:C10 (THC+CBD) extract, in conjunction with temozolomide and
radiotherapy for newly-diagnosed Glioblastoma patients.
While medical cannabis research has been an ongoing mission towards patient
treatment, this trial is unique because it is the culmination of a 10-year civil
society collaboration between the scientific sector and the medical cannabis
community. According to Dr. Juan Sepulveda, "Biological evidence has been
accumulating for more than 15 years that cannabinoids have anti-tumor activity
in the most aggressive brain tumors, glioblastomas. However, no clinical trials
have been conducted to prove this hypothesis in patients. With this clinical
trial, we can finally study the effect of cannabinoids on tumors that have not
received active treatment. With this trial, we are helping to give our patients
a new option, but also to open a therapeutic avenue. The trial is the result of
a collaboration between civil society through the Medical Cannabis Bike Tour, an
emerging pharmaceutical company and clinical scientists."
In 2013, the Medical Cannabis Bike Tour began raising funds to support the work
of the Complutense Madrid University team. Guided by Dr. Manuel Guzmán and Dr.
Guillermo Velasco, the team (http://cannabinoidsignalling.com/?lang=en) at
Cannabinoid Signalling Group
(https://aphriainc.sharepoint.com/:w:/s/Communications/EdOXmIimABNCnJAnQs8Tg-AB-
2xJuDx8bqA2lfuz1F-n4g?e=brOfQO) was researching the effects of cannabinoids on
cancer cells and the potential as a glioblastoma treatment. Today, with proceeds
from the Medical Cannabis Bike Tour founded by Luc Krol from the Netherlands-
based cannabis genetics seed bank, Paradise Seeds, (https://www.paradise-
seeds.com/) the Medical Bike Tour Foundation mobilized the European cannabis
community. It attracted significant sponsorship from the industry over the
course of five events held in different European countries who were advocates
for the impact of medical cannabis and its benefits. As a result, Luc Krol
passionately adds, "The world was very different when we began the Medical
Cannabis Bike Tour 10 years ago. We believed in the outstanding work of doctors
including Dr. Guzman and Velasco and their team and asked the cannabis community
for their support. The fact that the Medical Cannabis Bike Tour can now
independently fund a clinical trial in the name of science, is amazing thanks to
the sponsors and riders who made it happen. We hope this trial will reflect the
hope illuminated by the scientific research for the participants involved."
Tilray Medical's mission is to continue transforming lives and fostering dignity
for patients in need through access to medical cannabis, and today is a leading
provider of EU-GMP certified medical cannabis products in 20 countries with a
comprehensive portfolio of THC and CBD products. Tilray has supported medical
trials globally, across Europe, Canada, the United States, Australia, and Latin
America, studying the efficacy of medical cannabis as a treatment for
indications including pediatric epilepsy, refractory pediatric epilepsy, cancer-
induced nausea and vomiting, HIV, essential tremor, breast cancer disorders,
post-traumatic stress disorder, and alcohol use disorders.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for
patients in need through safe and reliable access to a global portfolio of
medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and
Navcora. Tilray grew from being one of the first companies to become an approved
licensed producer of medical cannabis in Canada to building the first GMP-
certified cannabis production facilities in Europe, first in Portugal and later
in Germany. Today, Tilray Medical is one of the largest suppliers of medical
cannabis to patients, physicians, hospitals, pharmacies, researchers, and
governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe
(https://www.globenewswire.com/Tracker?data=m1Az_-
tnZsDoxlCSp1pH3PiHCRFdInquYDLx5KVOa5GvwgptPn-Y03vYkHWZuF7Rh0qzejtpD0bwQw5JnkE1N-
U1p6NjeMmon6R86RJPFAM=), Tilray Medical Canada
(https://www.globenewswire.com/Tracker?data=m1Az_-
tnZsDoxlCSp1pH3M7b_XWARNG39Rhp4xd_74ETPGRj-
em6EdbrJPXjQUkShShdXNmHTuUrEACd5ypVnDKFsbnrvkhk13DIfhM-B8Y=), and Tilray Medical
Australia-New Zealand (https://www.globenewswire.com/Tracker?data=m1Az_-
tnZsDoxlCSp1pH3HeDgfzU3JETDxn_Mpdiawn_9p19CEaojZ8oRT7lcU-RvyLW7rZ-
zlbpHV1Op52byqeZmwj_WQtRZZZ-
kluYPvIbFvWYFney9hFXb7pRaj41qM9VasXi_RLhwyriMjmqgA==).
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-
lifestyle and consumer packaged goods company with operations in Canada, the
United States, Europe, Australia, and Latin America that is changing people's
lives for the better - one person at a time. Tilray Brands delivers on this
mission by inspiring and empowering the worldwide community to live their very
best life and providing access to products that meet the needs of their mind,
body, and soul while invoking wellbeing. Patients and consumers trust Tilray
Brands to deliver a cultivated experience and health and wellbeing through high-
quality, differentiated brands and innovative products. A pioneer in cannabis
research, cultivation, and distribution, Tilray's unprecedented production
platform supports over 20 brands in over 20 countries, including comprehensive
cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing, visit www.Tilray.com
(https://www.globenewswire.com/Tracker?data=fzsvaN9xcjfuytJbRROM8P8EfXdyJ5CovSdR
FsN99rXTVzlcyrmVWdiYCWOgUWWiwbZZoaGnvgnQs_u9-0OhNQ==).
Cautionary Statement Concerning Forward-Looking Statements
Certain statements in this press release constitute forward-looking information
or forward-looking statements (together, "forward-looking statements") under
Canadian securities laws and within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, that are intended to be subject to the "safe harbor" created
by those sections and other applicable laws. Forward-looking statements can be
identified by words such as "forecast," "future," "should," "could," "enable,"
"potential," "contemplate," "believe," "anticipate," "estimate," "plan,"
"expect," "intend," "may," "project," "will," "would" and the negative of these
terms or similar expressions, although not all forward-looking statements
contain these identifying words. Certain material factors, estimates, goals,
projections or assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations. Many factors could cause
actual results, performance or achievement to be materially different from any
forward-looking statements, and other risks and uncertainties not presently
known to the Company or that the Company deems immaterial could also cause
actual results or events to differ materially from those expressed in the
forward-looking statements contained herein. For a more detailed discussion of
these risks and other factors, see the most recently filed annual information
form of the Company and the Annual Report on Form 10-K (and other periodic
reports filed with the SEC) of the Company made with the SEC and available on
EDGAR. The forward-looking statements included in this communication are made as
of the date of this communication and the Company does not undertake any
obligation to publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by applicable
securities laws.
Contacts:
Tilray Brands:
Berrin Noorata
news@tilray.com
(https://www.globenewswire.com/Tracker?data=jldayMbnqvnympKO10Q24pLh1DvEQoLHFaw5
rHQAJKqWhXbA32F9Lz_2FnedH_GzMJqkkBucA7nW06u-Z45DLg==)
Investors
Raphael Gross
203-682-8253
Raphael.Gross@icrinc.com
(https://www.globenewswire.com/Tracker?data=4LeQXAMLOfOsyauLYTt4jszYDKAxaeWujc1E
0wACJati0QzHDlBP-sAwfsu8zJVYSzpRtgD8b1aNfkXiWcwXXJBpO0IdYNrN63OOiST7BpA=)
Medical Cannabis Bike Tour Foundation
press@medicalcannabis-biketour.com (mailto:press@medicalcannabis-biketour.com)
Â